Skip to content
Medical Health Aged Care

Memory Walk & Jog is heading to The Hunter!

Dementia Australia 2 mins read

What started as one event has grown to a movement across Australia, and in six weeks Memory Walk & Jog will take place in The Hunter region.

 

Dementia Australia’s largest fundraising event is heading back to The Hunter region after a great event last year with walkers, runners and joggers setting off on Sunday 12 May at Speers Point Park, Speers Point. Last year, more than 10,000 people walked, jogged and ran in cities and towns across Australia for people impacted by dementia. This year we’re hoping to go even bigger and want more people to sign-up and assist us in raising more than $2 million which will help fund invaluable support, education and resources for people living with dementia in Australia, their families and carers.

 

There are more than 421,000 people of all ages living with dementia in Australia. Without a medical breakthrough, the number of people living with dementia is expected to increase to more than 812,500 by 2054. Dementia is the second leading cause of death in Australia and the leading cause of death for women. Memory Walk & Jog plays an important role not only in funding support, but also in raising awareness of dementia.    

 

 Walk or jog with us. We are in this together. 

 

Sign-up to walk, jog or run, or join in as a Volunteer, at a Memory Walk & Jog event at www.memorywalk.com.au. Share your Memory Walk & Jog experience on your socials and Donate today to support people living with dementia across Australia. 

 

If you can’t attend an event, why not organise your own group or individual walk or jog, with a My Way event. Choose your own date and location and register at www.memorywalk.com.au/get-involved/mw

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.  

 

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au   

 

-Ends-

Media contacts: Ash Blakemore, Senior Media & Communications Advisor, 0448 170 672, ash.blakemore@dementia.org.au. Andrea Hogan, Media and Communications Manager, 0406 904 118, andrea.hogan@dementia.org.au

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors: Photos and video of previous Memory Walk & Jog events are available for publication.

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Medical Health Aged Care
  • 17/09/2024
  • 22:56
Ripple Therapeutics

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.Ripple's patented technology platform is based on…

  • Medical Health Aged Care
  • 17/09/2024
  • 15:11
Galderma

Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024

Late-breaking presentations will reveal important new data from the phase III OLYMPIA and ARCADIA trials, including durability and long-term efficacy of nemolizumab in prurigo…

  • Contains:
  • Engineering, Medical Health Aged Care
  • 17/09/2024
  • 08:40
UNSW Sydney

New electricity-free soft robot could aid precise surgery

Biomedical engineers have developed a new soft robotic system that works without electricity or motors, allowing for more precise surgeries at lower cost. The…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.